TIVC — Valion Bio, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1787740 ·
Last close
Market Cap
52W High
52W Low
ADV30
Next earnings
Valion Bio, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc. and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -5,634,000 -6,202,000 38,215,000 7,215,000 27,153,000
Dec 2025 -302,000 -1,975,000 -2,849,000 31,607,000 12,645,000 14,810,000
Sep 2025 146,000 -145,000 -2,483,000 -2,596,000 6,229,000 3,450,000 638,000
Jun 2025 86,000 54,000 -1,934,000 -1,931,000 4,508,000 1,184,000 821,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,619,000
Investing CF
$-705,000
Financing CF
$18,347,000
CapEx
$-581,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-10.61
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-52,597,000
Inventory
$4,000
Receivables
$19,000
ST Investments
EBIT TTM
$-7,847,000
Pretax Income TTM
$-7,993,000
Interest Exp TTM
Analysts

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -7,898,000 -8,878,000 31,607,000 14,810,000 -6,999,000
Dec 2024 0 -4,476,000 -5,655,000 2,807,000 272,000 -5,725,000
Dec 2023 1,176,000 -8,245,000 -8,244,000 5,157,000 1,577,000 -8,511,000
Dec 2022 1,840,000 -10,098,000 -10,096,000 5,875,000 2,245,000 -8,919,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-24.00

Peers — same industry

TickerNameMarket CapLastDaily %
ISRG INTUITIVE SURGICAL INC $154.64B $436.64
SYK STRYKER CORP $119.99B $313.00
MDT Medtronic plc $99.63B $77.60
BSX BOSTON SCIENTIFIC CORP $85.67B $57.64
MMM 3M CO $80.34B $154.03

News headlines (Yahoo Finance, 1h cache)

VALION BIO RECEIVES FIRST FDA-PRECEDENT STUDY PROTOCOL FROM NIAID FOR ENTOLIMOD™; FEDERAL AGENCY TO FULLY FUND BLA-ENABLING IN VIVO PROGRAM AND CO-NAVIGATE FDA SUBMISSION
2026-05-05 12:00 · Yahoo
Valion Bio Appoints Melinda Lackey as General Counsel
2026-05-04 20:05 · Yahoo
VALION BIO BRIEFS PENTAGON LEADERSHIP ON ENTOLIMOD™ FOR ACUTE RADIATION SYNDROME
2026-04-28 12:01 · Yahoo
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
2026-04-23 20:05 · Yahoo
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th
2026-04-15 12:00 · Yahoo
Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod
2026-03-31 12:30 · Yahoo
Presenting on Emerging Growth Conference 91 Day 1 on April 1; Register to live stream
2026-03-31 11:00 · Yahoo
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference
2026-03-27 15:30 · Yahoo
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome
2026-03-26 12:30 · Yahoo
Tivic Reports Full Year 2025 Results
2026-03-25 20:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.